Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for children with ADHD at Urmia University clinics
IRCT20241228064189N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risperidone in attention deficit hyperactivity disorder (ADHD), sponsored by Urmia University of Medical Sciences. Primary endpoints: Severity of ADHD symptoms from the parents' perspective, Severity of ADHD symptoms from the physician’s perspective and 1 more. Started Sep 2025; status: completed.
02
Drugs
risperidone
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20241228064189N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241228064189N1.